Hold ... However, news of the deprioritization has spooked investors hoping for a windfall of test sales in the U.S., halving the company’s shares price at market open this morning.
Despite the news, Sona CEO David Regan remains hopefully and said the demand for these tests in the private sector continues to grow.
“Large companies, employing thousands of people, are telling us that they cannot source rapid antigen tests which they view as critical to their business continuity and for the safety of their employees,” he added.
source : https://themarketherald.ca/sona-nanotech-csesona-shares-plunge-on-fda-ruling-2020-10-29/